File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Central administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice

TitleCentral administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in mice
Authors
Issue Date2014
PublisherFederation of American Societies for Experimental Biology. The Journal's web site is located at http://www.fasebj.org/
Citation
The 2014 Annual Meeting of Experimental Biology (EB 2014), San Diego, CA., 26-30 April 2014. In The FASEB Journal, 2014, v. 28 suppl. 1, abstract no. LB618 How to Cite?
AbstractC-X-C chemokine receptor type 4 (CXCR4) is an emerging area of pain hypersensitivity in the peripheral nervous system; however, its role in the central nervous system (CNS) for pain processing remains unclear. This study aimed at exploring the function of central CXCR4 in pain processing in vivo using its specific antagonist AMD3100 and partial sciatic nerve ligation (pSNL) model of peripheral neuropathic pain in C57BL/6 mice. A single intrathecal (central) administration of AMD3100 (intrathecal AMD3100, 5 μg) was found to prevent the development of pSNL-induced allodynia. Intrathecal AMD3100 (1 μg, 5 μg and 25 μg) also reversed the established pSNL-induced mechanical allodynia in a dose-dependent way on post-operative day 7 (POD 7). In rotarod test, intrathecal AMD3100 of different dosages (1 μg, 5 μg and 25 μg) did not impair the motor function of mice. Among mitogen-activated protein kinases (MAPKs) pathways, intrathecal AMD3100 was found to downregulate the activation of JNK1 and p38 pathway signaling proteins in the L3-L5 spinal cord segment as assessed by western blotting on POD 7. Our results firstly suggest that central (spinal) CXCR4 appears to be involved in the development and maintenance of peripheral neuropathic pain, implicating that CXCR4 would potentially be a therapeutic target for chronic neuropathic pain.
DescriptionConference Theme: Transforming the Future through Science
Session: Pharmacology and Experimental Therapeutics - Neuropharmacology
Persistent Identifierhttp://hdl.handle.net/10722/203690
ISSN
2015 Impact Factor: 5.299
2015 SCImago Journal Rankings: 2.775

 

DC FieldValueLanguage
dc.contributor.authorLuo, Xen_US
dc.contributor.authorTai, WLen_US
dc.contributor.authorSun, LTen_US
dc.contributor.authorQiu, Qen_US
dc.contributor.authorXia, Zen_US
dc.contributor.authorChung, SKen_US
dc.contributor.authorCheung, CWen_US
dc.date.accessioned2014-09-19T16:11:25Z-
dc.date.available2014-09-19T16:11:25Z-
dc.date.issued2014en_US
dc.identifier.citationThe 2014 Annual Meeting of Experimental Biology (EB 2014), San Diego, CA., 26-30 April 2014. In The FASEB Journal, 2014, v. 28 suppl. 1, abstract no. LB618en_US
dc.identifier.issn0892-6638-
dc.identifier.urihttp://hdl.handle.net/10722/203690-
dc.descriptionConference Theme: Transforming the Future through Science-
dc.descriptionSession: Pharmacology and Experimental Therapeutics - Neuropharmacology-
dc.description.abstractC-X-C chemokine receptor type 4 (CXCR4) is an emerging area of pain hypersensitivity in the peripheral nervous system; however, its role in the central nervous system (CNS) for pain processing remains unclear. This study aimed at exploring the function of central CXCR4 in pain processing in vivo using its specific antagonist AMD3100 and partial sciatic nerve ligation (pSNL) model of peripheral neuropathic pain in C57BL/6 mice. A single intrathecal (central) administration of AMD3100 (intrathecal AMD3100, 5 μg) was found to prevent the development of pSNL-induced allodynia. Intrathecal AMD3100 (1 μg, 5 μg and 25 μg) also reversed the established pSNL-induced mechanical allodynia in a dose-dependent way on post-operative day 7 (POD 7). In rotarod test, intrathecal AMD3100 of different dosages (1 μg, 5 μg and 25 μg) did not impair the motor function of mice. Among mitogen-activated protein kinases (MAPKs) pathways, intrathecal AMD3100 was found to downregulate the activation of JNK1 and p38 pathway signaling proteins in the L3-L5 spinal cord segment as assessed by western blotting on POD 7. Our results firstly suggest that central (spinal) CXCR4 appears to be involved in the development and maintenance of peripheral neuropathic pain, implicating that CXCR4 would potentially be a therapeutic target for chronic neuropathic pain.-
dc.languageengen_US
dc.publisherFederation of American Societies for Experimental Biology. The Journal's web site is located at http://www.fasebj.org/-
dc.relation.ispartofThe FASEB Journalen_US
dc.titleCentral administration of C-X-C chemokine receptor type 4 antagonist alleviates the development and maintenance of peripheral neuropathic pain in miceen_US
dc.typeConference_Paperen_US
dc.identifier.emailSun, LT: ltsun@hku.hken_US
dc.identifier.emailXia, Z: zyxia@hkucc.hku.hken_US
dc.identifier.emailChung, SK: skchung@hkucc.hku.hken_US
dc.identifier.emailCheung, CW: cheucw@hku.hken_US
dc.identifier.authorityXia, Z=rp00532en_US
dc.identifier.authorityChung, SK=rp00381en_US
dc.identifier.authorityCheung, CW=rp00244en_US
dc.identifier.hkuros235623en_US
dc.identifier.volume28en_US
dc.identifier.issuesuppl. 1en_US
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats